SEC recommends COVID-19 vaccination of children aged 2 to 18 years
Bharat Biotech's Covaxin has finally been approved for emergency use for children aged from 2 to 18 years. The Subject Expert Committee (SEC) constituted on COVID-19 has recommended this vaccine. Hyderabad-based pharmaceutical company Bharat Biotech completed Phase II and III trials of Covaxin on children below 18 years of age in September. In the first week of October, the trial data was submitted to the Drugs Controller General of India. This indigenous vaccine will be administered in two doses at an interval of 20 days. With last day's administration of 65,86,092 COVID-19 vaccine doses, the total number has reached 95,89,78,049 in the country.